Correlation of SATB1 expression with clinical course of cutaneous T-cell lymphomas

Polish Journal of Pathology

Volumn 63, Issue 2, 2012, Pages 101-105

  Grzanka, Aleksandra ^a   Grzanka, Dariusz ^b   Gagat, Maciej ^b   Tadrowski, Tadeusz ^a   Sokołowska Wojdył o, Malgorzata ^c   Marszałek, Andrzej ^a,d   Placek, Waldemar ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

CTCL; Cutaneous T cell lymphoma; Mycosis fungoides; Prognostic marker; SATB1

Indexed keywords

MATRIX ATTACHMENT REGION BINDING PROTEIN; SATB1 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BIOSYNTHESIS; CANCER STAGING; CUTANEOUS T CELL LYMPHOMA; DISEASE COURSE; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SKIN TUMOR;

DISEASE PROGRESSION; FEMALE; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MATRIX ATTACHMENT REGION BINDING PROTEINS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84864830516     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol 2007; 143: 854-859.
2. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785.
3. Swerdlow SH. Campo E, Harris NL, et al. Classification of Tumors of Hematopoietic and Lymphoid Tissues. IARC Press, Lyon 2008.
4. PlacekW, Grzanka AA. Poste{ogonek}py w leczeniu chłoniaków skóry. Przegl Dermatol 2006; 93 nr spec. s153-159
5. Marszałek A, Grzanka A, Grzanka D, Placek W. Correct answer to the quiz. Check your diagnosisMycosis fungoides-case report and short overview of the literature. Pol J Pathol 2010; 61: 54-61.
6. Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/ Sézary syndrome. Eur. J Cancer 2006; 42: 1014-1030.
7. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713-1722.
8. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumors ofHaematopoietic and Lymphoid Tissues. IARC Press, Lyon 2008.
9. Dickinson LA, Joh T, Kohwi Y, Kohwi-Shigematsu T. A tissue-specificMAR/SAR DNA-binding protein with unusual binding site recognition. Cell 1992; 70: 631-645.
10. Yasui D, Miyano M, Cai S, et al. SATB1 targets chromatin remodelling to regulate genes over long distances. Nature 2002; 419: 641-645.
11. Alvarez JD, Yasui DH, Niida H, et al. The MAR-binding protein SATB1 orchestrates temporal and spatial expression of multiple genes during T-cell development. Genes Dev 2000; 14: 521-535.
12. Han H, Russo J, Kohwi Y, Kohwi-Shigematsu T. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature 2008; 452: 187-193.
13. Patani N, Jiang W, Mansel R, Newbold R, Mokbel K. The mRNA expression of SATB1 and SATB2 in human breast cancer. Cancer Cell Int 2009; 9: 18.
14. Zhou L, Liu F, Tong J, et al. Expression of special AT-rich sequence-binding protein mRNA and its clinicopathological significance in non-small cell lung cancer. Nan Fang Yi Ke Da Xue Xue Bao 2009; 29: 534-537.
15. Zhao X, JiW, ZhangW, et al. Overexpression of SATB1 in laryngeal squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec 2010; 72: 1-5.
16. Liu C, Wen Y, Xu K, et al. [Expression of special AT-rich sequence-binding protein in bladder urothelial carcinoma and its clinical significance.]. Nan Fang Yi Ke Da Xue Xue Bao 2010; 30: 1389-1391.
17. Lorns E, HnatyszynHJ, Seo P, et al. The Role of SATB1 in breast cancer pathogenesis. J Natl Cancer Inst 2010; 102: 1284-1296.
18. Hawkins SM, Kohwi-Shigematsu T, Skalnik DG. The matrix attachment region-binding protein SATB1 interacts with multiple elements within the gp91phox promoter and is down-regulated during myeloid differentiation. J Biol Chem 2001; 276: 44472-44480.
19. Sun Y, Wang T, Su Y, et al. The behavior of SATB1, a MARbinding protein, in response to apoptosis stimulation. Cell Biol Int 2006; 30: 244-247.
20. de Belle I, Cai S, Kohwi-Shigematsu T. The genomic sequences bound to special AT-rich sequence-binding protein 1 (SATB1) in vivo in Jurkat T cells are tightly associated with the nuclear matrix at the bases of the chromatin loops. J Cell Biol 1998; 141: 335-348.
21. Notani D, Gottimukkala KP, Jayani RS, et al. Global regulator SATB1 recruits β-Catenin and regulates TH2 differentiation inWnt-Dependent manner. PLoS Biol 2010; 8: e1000296.
22. Wang Y, Su M, Zhou LL, et al. Deficiency of SATB1 expression in Sezary cells causes apoptosis resistance by regulating FasL/CD95L transcription. Blood 2011; 117: 3826-3835.
23. Contassot E, French LE. Targeting apoptosis defects in cutaneous T-cell lymphoma. J Invest Dermatol 2009; 129: 1059-1061.
24. Ni X, Zhang C, Talpur R, Duvic M. Resistance to activationinduced cell death and bystander cytotoxicity via the Fas/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas. J Invest Dermatol 2005; 124: 741-750.
25. Chen H, TakaharaM, Oba J, et al. Clinicopathologic and prognostic significance of SATB1 in cutaneousmalignantmelanoma. J Dermatol Sci 2011; 64: 39-44.